| Added by | mollevi |
|---|---|
| Group name | EquipeJC |
| Item Type | Note |
| Note | The following values have no corresponding Zotero field: auth-address: UMR1098, University of Bourgogne France-Comte Department of Medical Oncology, INSERM UMR1098. IRCM-INSERM U1194, Institut de Recherche en Cancerologie de Montpellier. Umr1098, inserm. UMR1098, EFS Bourgogne France-Comte UMR INSERM-UFC-EFS 1098, Universite de Franche Comte Department of Medical Oncology, University Hospital of Besancon. Department of Medical Oncology, University Hospital Besancon. Department of Pharmacology, Univeristy Hospital of Besancon. Immunopathologie et immunointervention therapeutique, INSERM U872, Centre de recherche des Cordeliers, Universite Pierre et Marie Curie and Universite Paris Descartesn UMR-sante 872. Department of Biological Immunology, Hopital Europeen Georges Pompidou. Department of Medical Oncology, Univeristy Hospital of Besancon. University of Bourgogne Franche-Comte, INSERM UMR1098. INSERM UMR1098, University of Bourgogne France-Comte Medical Oncology, INSERM, UMR1098 olivier.adotevi@univ-fcomte.fr. alt-title: Cancer research accession-num: 27197194 |
| Tags | _EndnoteXML import |
| Date Added | 2018/11/14 - 11:48:35 |
| Date Modified | 2018/11/14 - 11:48:35 |
| Parent item | Rapalogs efficacy relies on the modulation of antitumor T cell immunity |
Institut de Recherche en Cancérologie de
